-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FPA-150 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPA-150 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPA-150 in Metastatic Breast Cancer Drug Details: FPA-150 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Decitabine + Tetrahydrouridine) in Sickle Cell Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Decitabine + Tetrahydrouridine) in Sickle Cell Disease Drug Details: Decitabine in combination with tetrahydrouridine is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BBT-369 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BBT-369 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BBT-369 in Follicular Lymphoma Drug Details: BBT-369 is under development for the...
-
Product Insights
Acral Lentiginous Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Acral Lentiginous Melanoma - Drugs In Development, 2023’, provides an overview of the Acral Lentiginous Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acral Lentiginous Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Tenosynovial Giant Cell Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Tenosynovial Giant Cell Tumor - Drugs In Development, 2023’, provides an overview of the Tenosynovial Giant Cell Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tenosynovial Giant Cell Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Malignant Fibrous Histiocytoma of Soft Tissue – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Fibrous Histiocytoma of Soft Tissue - Drugs In Development, 2023’, provides an overview of the Malignant Fibrous Histiocytoma of Soft Tissue pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Fibrous Histiocytoma of Soft Tissue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Malignant Fibrous Histiocytoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Fibrous Histiocytoma - Drugs In Development, 2023’, provides an overview of the Malignant Fibrous Histiocytoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Fibrous Histiocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Salivary Gland Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Salivary Gland Cancer - Drugs In Development, 2023’, provides an overview of the Salivary Gland Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Salivary Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Anaplastic Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Anaplastic Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Anaplastic Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drugs In Development, 2023’, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...